Phase I study for simultaneous radiochemotherapy of relapsed ovarian cancer - Ovaradrez

niversitätsklinikum für Strahlentherapie0 个研究点目标入组 6 人开始时间: 2015年5月29日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

•1. patient with initial histologically confirmed, abdominally relapsed malignant serous, mucinous or endometrioid ovarian cancer, carcinoma of the tube, or primary peritoneal.
•2. platinum-sensitive or platinum-refractory relapse into the peritoneal cavity and simultaneously in subdiaphragmal nearby lymph nodes
•3. adequate renal function (calculated GFR> 60 mL / min acc. Cockcroft-Gault formula) and normal liver function (ALT, AST, bilirubin
•4. Minimum age 18 years

•1. recurrence surgery promising or necessity of immediate surgery
•2. Other malignant neoplasm in history except basal cell carcinoma
•3. Karnofsky index below 40% (= disabled, skilled help needed)
•4. contrast agent allergy
•5. Participation in other clinical study
•6. symptomatic adhesions after previous abdominal or pelvic surgery
•7. pre-existing bowel disease
•8. Clear cell tumor, germ cell tumor, yolk sac tumor or borderline tumor of the ovary
•9. inability arms to store high
•10. bone marrow dysfunction, thrombocytopenia, leukopenia
•11 serious multimorbidity
•12. bleeding
•13.extraabdominelle distant metastases, liver metastases
•14. relevant renal or hepatic impairment
•15. application of bevacizumab in the past 4 weeks (because of the associated risk of bowel perforation)

发起方

niversitätsklinikum für Strahlentherapie